Massive tumor study counts rare gene fusions
NCT ID NCT04010240
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study examined tumor samples from 3820 people with advanced solid tumors to find how many have NTRK gene fusions. Researchers used genetic testing to identify these rare changes. The study did not test any treatment, but aims to guide future targeted therapy decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify which patients might benefit from targeted NTRK inhibitor therapies.
- What could go wrong
- This is an observational study only—it does not test any treatment. Results may not change how patients are treated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié
Bordeaux, Aquitaine, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can your own immune cells fight advanced cancer?
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?